Intercalated TKI and chemotherapy induction in EGFR mt+ NSCLC stage IIIA and IIIB: report of 3 cases with complete pathologic remission in mediastinal lymph nodes
F Griesinger, A Lüers, M Falk, I Conradi, M Reinhardt, A Kluge, K Willborn, R Prenzel, DC Scriba, R Henke, W Eberhardt, C Hallas, M Tiemann · Pneumologie · 2016 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: EGFR TKI treatment is standard of care in patients with metastasized NSCLC carrying an activating EGFR mutation. However, induction concepts in locally advanced NSCLC with EGFR mutation have not been studied extensively. Recently new focus has been shed on intercalated regimens of chemotherapy and TKI, showing improved PFS as well as OS. This concept was used as induction regimen in 3 patients with activating EGFR mutation in stages IIIA and IIIB. Methods: Patients were diagnosed according to standard imaging, histology and immunohistology methods. EGFR, KRAS, BRAF, ALK and P53 mutation analysis were…
